These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 30102194)

  • 21.
    De Bruycker S; Vangestel C; Van den Wyngaert T; Pauwels P; Wyffels L; Staelens S; Stroobants S
    J Nucl Med; 2019 Jan; 60(1):34-40. PubMed ID: 29980581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stereotactic radiotherapy (SBRT) as a sole or salvage therapy in non-small cell lung cancer patients.
    Dworzecki T; Idasiak A; Syguła D; Dworzecka U; Suwiński R
    Neoplasma; 2012; 59(1):114-20. PubMed ID: 22103905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pretreatment [18F]-fluoro-2-deoxy-glucose positron emission tomography maximum standardized uptake value as predictor of distant metastasis in early-stage non-small cell lung cancer treated with definitive radiation therapy: rethinking the role of positron emission tomography in personalizing treatment based on risk status.
    Nair VJ; MacRae R; Sirisegaram A; Pantarotto JR
    Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):312-8. PubMed ID: 24411602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor Control and Toxicity for Common Stereotactic Body Radiation Therapy Dose-Fractionation Regimens in Stage I Non-Small Cell Lung Cancer.
    Stephans KL; Woody NM; Reddy CA; Varley M; Magnelli A; Zhuang T; Qi P; Videtic GMM
    Int J Radiat Oncol Biol Phys; 2018 Feb; 100(2):462-469. PubMed ID: 29353658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Helical image-guided stereotactic body radiotherapy (SBRT) for the treatment of early-stage lung cancer: a single-institution experience at the Willis-Knighton Cancer Center.
    Rosen LR; Fischer-Valuck BW; Katz SR; Durci M; Wu HT; Syh J; Syh J; Patel B
    Tumori; 2014; 100(1):42-8. PubMed ID: 24675490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
    Satoh Y; Onishi H; Nambu A; Araki T
    Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of stereotactic body radiation therapy for biopsy-proven versus radiographically diagnosed early-stage non-small lung cancer: a single-institution experience.
    Fischer-Valuck BW; Boggs H; Katz S; Durci M; Acharya S; Rosen LR
    Tumori; 2015; 101(3):287-93. PubMed ID: 25908031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients.
    Taremi M; Hope A; Dahele M; Pearson S; Fung S; Purdie T; Brade A; Cho J; Sun A; Bissonnette JP; Bezjak A
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):967-73. PubMed ID: 21377293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stereotactic body radiation therapy for re-irradiation of persistent or recurrent non-small cell lung cancer.
    Trovo M; Minatel E; Durofil E; Polesel J; Avanzo M; Baresic T; Bearz A; Del Conte A; Franchin G; Gobitti C; Rumeileh IA; Trovo MG
    Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1114-9. PubMed ID: 24661664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer-A Single Institution Experience With Long-Term Follow-Up.
    Karasawa K; Hayakawa S; Machitori Y; Shibata Y; Ogawa H; Ito K; Shimizuguchi T; Kawamoto T; Nihei K
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818806318. PubMed ID: 30317929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lung stereotactic body radiation therapy for elderly patients aged ≥ 80 years with pathologically proven early-stage non-small cell lung cancer: a retrospective cohort study.
    Watanabe K; Katsui K; Sugiyama S; Yoshio K; Kuroda M; Hiraki T; Kiura K; Maeda Y; Toyooka S; Kanazawa S
    Radiat Oncol; 2021 Feb; 16(1):39. PubMed ID: 33622369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes and toxicity of stereotactic body radiation therapy for advanced stage ultra-central non-small cell lung cancer.
    Cong Y; Sun B; Wang J; Meng X; Xuan L; Zhang J; Liu J; Shen G; Wu S
    Thorac Cancer; 2019 Jul; 10(7):1567-1575. PubMed ID: 31187604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A clinical study of shrinking field radiation therapy based on (18)F-FDG PET/CT for stage III non-small cell lung cancer.
    Ding X; Li H; Wang Z; Huang W; Li B; Zang R; Sun H; Yi Y
    Technol Cancer Res Treat; 2013 Jun; 12(3):251-7. PubMed ID: 23289475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiac Dose and Survival After Stereotactic Body Radiotherapy for Early-stage Non-Small-cell Lung Cancer.
    Tembhekar AR; Wright CL; Daly ME
    Clin Lung Cancer; 2017 May; 18(3):293-298. PubMed ID: 28089158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy.
    Lovinfosse P; Janvary ZL; Coucke P; Jodogne S; Bernard C; Hatt M; Visvikis D; Jansen N; Duysinx B; Hustinx R
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1453-60. PubMed ID: 26830299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential inflammatory response dynamics in normal lung following stereotactic body radiation therapy with protons versus photons.
    Li Y; Dykstra M; Best TD; Pursley J; Chopra N; Keane FK; Khandekar MJ; Sharp GC; Paganetti H; Willers H; Fintelmann FJ; Grassberger C
    Radiother Oncol; 2019 Jul; 136():169-175. PubMed ID: 31015121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognositc significance of SUV
    Dong M; Liu J; Sun X; Xing L
    J Med Imaging Radiat Oncol; 2017 Oct; 61(5):652-659. PubMed ID: 28266166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reirradiation of recurrent node-positive non-small cell lung cancer after previous stereotactic radiotherapy for stage I disease : A multi-institutional treatment recommendation.
    Nieder C; De Ruysscher D; Gaspar LE; Guckenberger M; Mehta MP; Cheung P; Sahgal A
    Strahlenther Onkol; 2017 Jul; 193(7):515-524. PubMed ID: 28424839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating Tumor Cell Assessment in Presumed Early Stage Non-Small Cell Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy: A Prospective Pilot Study.
    Frick MA; Kao GD; Aguarin L; Chinniah C; Swisher-McClure S; Berman AT; Levin WP; Cengel KA; DeCesaris C; Hahn SM; Dorsey JF; Simone CB
    Int J Radiat Oncol Biol Phys; 2018 Nov; 102(3):536-542. PubMed ID: 30244877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of Distant Failure After Stereotactic Body Radiation Therapy for Stages I to IIA Non-Small-Cell Lung Cancer.
    Miller CJ; Martin B; Stang K; Hutten R; Alite F; Small C; Emami B; Harkenrider MM
    Clin Lung Cancer; 2019 Jan; 20(1):37-42. PubMed ID: 30279109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.